DULUTH, GA, December 07, 2012 /24-7PressRelease/
, a master distributor and manufacturer of medical devices, today announced the publication of its latest white paper, Reinventing a Better babyLance Infant Heel Incision Device: Defining, Translating and Validating Ergonomic Design Specifications
The new white paper describes how MediPurpose successfully:
* Gathered end-users' expectations for an ergonomic neonatal heel incision device.
* Translated those expectations into design specifications.
* Validated new design ergonomics before launching its all-new babyLance infant heelstick
in August 2012.
According to the white paper, throughout the babyLance reinvention process, MediPurpose painstakingly evaluated virtually every component and feature of its new neonatal heel incision device
as it engaged with end-users to better understand their expectations and requirements for the ideal heelstick. Along with end-user performance needs, MediPurpose recognized ergonomics as an equally important design priority.
"When we initiated the redesign of our babyLance infant heelstick, we took an extremely thoughtful and meticulous approach to developing a device that had superior form and function," said MediPurpose founder and CEO Patrick Yi. "We were keenly aware that success would require more than just collecting user input and feeding it to the design team. Instead, it would demand a very interactive, reciprocal process that ensured harmony between what its users wanted and what the design team produced."
The white paper also explains how MediPurpose created an "ergonomics requirement and design specifications matrix" to guide the process. This matrix comprehensively outlined end-user ergonomic requirements so its design team could collaboratively translate them into specific solutions for the final babyLance design.
About babyLance Infant Heelsticks
The new babyLance infant heel incision device is a fully redesigned iteration of MediPurpose's original safe, easy and effective heelstick device.
Used by neonatal caregivers to collect blood samples from infants, the new babyLance features an ergonomic design to provide a secure and stable grip.
Combined with a redesigned trigger mechanism, the heelstick device is easy to activate, helping to deliver a consistent incision without damaging the baby's tender nerve fibers.
babyLance heelstick devices are available in two models:
* The babyLance BLP (Preemie), which delivers an incision depth of 0.85 mm.
* The babyLance BLN (Newborn), which delivers an incision depth of 1.00 mm.
To download the white papers, please visit http://www.medipurpose.com/downloads.
For more information about babyLance -- including pricing and no-cost product sample requests -- please visit http://www.medipurpose.com/babylance.About MediPurpose
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance(tm) heel incision device, SurgiLance(tm) safety lancet and MediPlus(tm) advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and distributors.
MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com